Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,281 | 359 | 98.6% |
| Education | $127.35 | 7 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,722 | 43 | $0 (2024) |
| ABBVIE INC. | $1,099 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $769.63 | 41 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $651.74 | 29 | $0 (2023) |
| Amgen Inc. | $634.61 | 15 | $0 (2024) |
| Lilly USA, LLC | $617.52 | 32 | $0 (2024) |
| Novo Nordisk Inc | $617.16 | 20 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $581.58 | 27 | $0 (2023) |
| Astellas Pharma US Inc | $526.58 | 21 | $0 (2023) |
| Amarin Pharma Inc. | $319.13 | 12 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $578.41 | 6 | ABBVIE INC. ($207.64) |
| 2023 | $1,210 | 29 | GlaxoSmithKline, LLC. ($297.04) |
| 2022 | $1,648 | 64 | GlaxoSmithKline, LLC. ($419.36) |
| 2021 | $1,498 | 68 | AbbVie Inc. ($468.38) |
| 2020 | $210.95 | 7 | GlaxoSmithKline, LLC. ($131.25) |
| 2019 | $1,309 | 45 | GlaxoSmithKline, LLC. ($349.07) |
| 2018 | $1,206 | 53 | Amgen Inc. ($259.65) |
| 2017 | $1,748 | 94 | SANOFI-AVENTIS U.S. LLC ($252.60) |
All Payment Transactions
366 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $113.30 | General |
| Category: RESPIRATORY | ||||||
| 08/27/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $137.61 | General |
| Category: Bone Health | ||||||
| 08/22/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $119.25 | General |
| Category: NEUROSCIENCE | ||||||
| 08/14/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Oncology | ||||||
| 04/09/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $100.43 | General |
| Category: Obesity | ||||||
| 02/08/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $88.39 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $81.28 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $111.72 | General |
| Category: Biological | ||||||
| 05/26/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/23/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.27 | General |
| 05/22/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Diabetes | ||||||
| 05/18/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: VACCINES | ||||||
| 05/17/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $66.34 | General |
| Category: Diabetes | ||||||
| 05/11/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: Diabetes | ||||||
| 05/09/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $119.11 | General |
| 05/03/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Diabetes Care | ||||||
| 04/27/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: NEUROSCIENCE | ||||||
| 04/11/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: VACCINES | ||||||
| 04/04/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $94.94 | General |
| 04/04/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $16.67 | General |
| 03/23/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: DIABETES | ||||||
| 03/14/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/09/2023 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,143 | 1,879 | $498,338 | $122,245 |
| 2022 | 39 | 2,103 | 3,257 | $616,262 | $183,879 |
| 2021 | 47 | 2,368 | 3,626 | $547,336 | $152,062 |
| 2020 | 37 | 2,207 | 3,607 | $557,721 | $146,005 |
All Medicare Procedures & Services
147 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 76 | 426 | $132,240 | $43,080 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 182 | 405 | $169,365 | $33,216 | 19.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 125 | 125 | $54,345 | $15,875 | 29.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 17 | 85 | $15,010 | $3,202 | 21.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 17 | 85 | $11,560 | $3,089 | 26.7% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 112 | 112 | $11,871 | $2,815 | 23.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 11 | 11 | $10,837 | $2,805 | 25.9% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 36 | 37 | $22,157 | $2,145 | 9.7% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 113 | 113 | $8,741 | $2,038 | 23.3% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 25 | 25 | $6,625 | $1,927 | 29.1% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 100 | 100 | $7,590 | $1,802 | 23.7% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 11 | 11 | $7,021 | $1,770 | 25.2% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 45 | 45 | $9,170 | $1,694 | 18.5% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 31 | 31 | $9,938 | $1,691 | 17.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 20 | 20 | $2,200 | $1,516 | 68.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 23 | $6,925 | $1,182 | 17.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 34 | 35 | $3,108 | $1,061 | 34.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 39 | 39 | $3,016 | $299.15 | 9.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 12 | 13 | $1,246 | $287.24 | 23.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 23 | $1,698 | $211.09 | 12.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 33 | 35 | $899.00 | $177.80 | 19.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 11 | 11 | $1,550 | $168.80 | 10.9% |
| 81003 | Automated urinalysis test | Office | 2023 | 51 | 58 | $890.00 | $127.60 | 14.3% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 11 | 11 | $336.00 | $67.21 | 20.0% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 83 | 510 | $135,150 | $50,931 | 37.7% |
About Dr. Uzoamaka Obinabo, M.D
Dr. Uzoamaka Obinabo, M.D is a Family Medicine healthcare provider based in Bedford, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1992917413.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Uzoamaka Obinabo, M.D has received a total of $9,408 in payments from pharmaceutical and medical device companies, with $578.41 received in 2024. These payments were reported across 366 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($9,281).
As a Medicare-enrolled provider, Obinabo has provided services to 7,821 Medicare beneficiaries, totaling 12,369 services with total Medicare billing of $604,191. Data is available for 4 years (2020–2023), covering 147 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Bedford, TX
- Active Since 05/04/2007
- Last Updated 02/06/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1992917413
Products in Payments
- TRELEGY ELLIPTA (Drug) $736.36
- FARXIGA (Drug) $694.17
- JARDIANCE (Drug) $622.66
- SHINGRIX (Biological) $487.89
- UBRELVY (Drug) $486.74
- Vascepa (Drug) $319.13
- QULIPTA (Drug) $315.66
- Prolia (Biological) $315.62
- VRAYLAR (Drug) $308.15
- TOUJEO (Drug) $283.14
- Ozempic (Drug) $251.72
- AUSTEDO (Drug) $182.92
- NURTEC ODT (Drug) $177.85
- Myrbetriq (Drug) $163.45
- EVENITY (Biological) $161.05
- CONTRAVE (Drug) $156.19
- Horizant (Drug) $142.99
- VESICARE (Drug) $142.71
- ANORO (Drug) $141.34
- RYBELSUS (Drug) $136.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Bedford
Munawar Haider, Md, MD
Family Medicine — Payments: $14,495
Vasu Nalajala, Md, MD
Family Medicine — Payments: $13,823
Dr. Charles Cook, D.o, D.O
Family Medicine — Payments: $12,048
Dr. Kara Matala, D.o, D.O
Family Medicine — Payments: $11,758
Diane Rowell, Md, MD
Family Medicine — Payments: $8,868
Ajay Koshy, Md, MD
Family Medicine — Payments: $5,816